• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 6-K filed by IceCure Medical Ltd.

    7/10/25 8:05:29 AM ET
    $ICCM
    Medical/Dental Instruments
    Health Care
    Get the next $ICCM alert in real time by email
    6-K 1 ea0248433-6k_icecure.htm REPORT OF FOREIGN PRIVATE ISSUER

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 6-K

     

    REPORT OF FOREIGN PRIVATE ISSUER

    PURSUANT TO RULE 13a-16 OR 15d-16

    UNDER THE SECURITIES EXCHANGE ACT OF 1934

     

    For the Month of: July 2025 (Report No. 2)

     

    Commission File Number: 001-40753

     

    ICECURE MEDICAL LTD.

    (Translation of registrant’s name into English)

     

    7 Ha’Eshel St., PO Box 3163

    Caesarea, 3079504 Israel

    (Address of principal executive office)

     

    Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

     

    ☒ Form 20-F ☐ Form 40-F

     

     

     

     

     

    CONTENTS

     

    Preliminary Unaudited Financial Information for the Three and Six Month Periods Ended June 30, 2025

     

    IceCure Medical Ltd. (the “Company”) is providing the following preliminary financial information for the three and six month periods ended June 30, 2025.

     

    For the three and six month periods ended June 30, 2025, product sales were approximately $525,000 and $1.25 million, respectively. As a result of delayed shipments and lower sales for the three and six months ended June 30, 2025, due to the conflict between Israel and Iran and the absence of $100,000 in revenue from the exclusive distribution agreement with Terumo Corporation and other services in Japan that was recorded in the six month period ended June 30, 2024, gross profit and gross margin for the six months ended June 30, 2025 are expected to be significantly lower compared to the same period in 2024.

     

    The Company estimates that the lower revenue for the three and six months ended June 30, 2025 will not have a material effect on operating expenses, including research and development, sales and marketing, and general and administrative expenses, although such expenses may fluctuate for reasons unrelated to revenue levels. As a result of the lower revenue and gross profit expected for the six months ended June 30, 2025, net loss for the six months ended June 30, 2025 is expected to be higher compared to the net loss for the six months ended June 30, 2024.

     

    This preliminary financial information has been prepared solely on the basis of information that is currently available to, and that is the responsibility of, Company management. The Company’s independent registered public accounting firm has not audited nor reviewed, and does not express an opinion with respect to this information. This preliminary financial information is based upon the Company’s estimates, is not a comprehensive statement of loss for the six month period ended June 30, 2025 and remains subject to, among other things, the completion of the Company’s financial closing procedures, final adjustments, and completion of the Company’s internal review as of and for the six month period ended June 30, 2025, which may impact the results and expectations set forth above.

     

    Rights Offering Update

     

    On July 10, 2025, the Company issued a press release titled “IceCure Announces Commencement of Rights Offering”, a copy of which is furnished as Exhibit 99.1 with this Report of Foreign Private Issuer on Form 6-K.

     

    Incorporation by Reference

     

    This Report of Foreign Private Issuer on Form 6-K is incorporated by reference into the Company’s Registration Statements on Form F-3 (Registration Nos. 333-258660 and 333-267272) and Form S-8 (Registration Nos. 333-270982, 333-264578, 333-262620 and 333-281587), filed with the Securities and Exchange Commission, to be a part thereof from the date on which this Report of Foreign Private Issuer on Form 6-K is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.

     

    EXHIBIT INDEX

     

    Exhibit No.    
    99.1   Press release dated July 10, 2025, titled “IceCure Announces Commencement of Rights Offering.”

     

     1

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

     

      ICECURE MEDICAL LTD.
         
    Date: July 10, 2025 By: /s/ Eyal Shamir
        Name  Eyal Shamir
        Title: Chief Executive Officer

     

     

    2

     

     

    Get the next $ICCM alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $ICCM

    DatePrice TargetRatingAnalyst
    2/2/2022$5.65Buy
    Brookline Capital
    9/22/2021$14.50Buy
    Alliance Global Partners
    More analyst ratings

    $ICCM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Brookline Capital initiated coverage on Icecure Medical with a new price target

      Brookline Capital initiated coverage of Icecure Medical with a rating of Buy and set a new price target of $5.65

      2/2/22 11:13:08 AM ET
      $ICCM
      Medical/Dental Instruments
      Health Care
    • Alliance Global Partners initiated coverage on Icecure Medical with a new price target

      Alliance Global Partners initiated coverage of Icecure Medical with a rating of Buy and set a new price target of $14.50

      9/22/21 8:10:09 AM ET
      $ICCM
      Medical/Dental Instruments
      Health Care

    $ICCM
    SEC Filings

    See more
    • SEC Form 424B3 filed by IceCure Medical Ltd.

      424B3 - IceCure Medical Ltd. (0001584371) (Filer)

      7/28/25 7:48:24 AM ET
      $ICCM
      Medical/Dental Instruments
      Health Care
    • SEC Form 6-K filed by IceCure Medical Ltd.

      6-K - IceCure Medical Ltd. (0001584371) (Filer)

      7/28/25 7:26:35 AM ET
      $ICCM
      Medical/Dental Instruments
      Health Care
    • SEC Form 6-K filed by IceCure Medical Ltd.

      6-K - IceCure Medical Ltd. (0001584371) (Filer)

      7/25/25 9:05:02 AM ET
      $ICCM
      Medical/Dental Instruments
      Health Care

    $ICCM
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • IceCure Announces Expiration and Results of Approximately Two Times Over-Subscribed Rights Offering for Aggregate Gross Proceeds of $10.0 Million

      CAESAREA, Israel, July 29, 2025 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ:ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today announced that the subscription period of its previously announced rights offering (the "Rights Offering") expired at 5:00 p.m., Eastern Time, on July 28, 2025. As previously disclosed, the Company distributed to all holders of record of the Company's ordinary shares, no par value per share ("Ordinary Shares") as of 5:00 p.m., Eastern Time, on July 9, 2025 (the "Record Date"), at no charge, non-transferable subscription righ

      7/29/25 9:00:00 AM ET
      $ICCM
      Medical/Dental Instruments
      Health Care
    • IceCure's ProSense® Featured at Japanese Breast Cancer Society Conference: Updated Positive Clinical Data Shows 99% Recurrence Free Rate with Cryoablation

      Breast surgeon, Professor Eisuke Fukuma, a highly regarded cryoablation expert & ProSense® user at Kameda Medical Center, presented updated breast cancer cryoablation data from an independent study of over 600 women from 2006 to 2023 Independent ProSense® study by Professor Hisanori Kawamoto demonstrating 0% breast cancer local recurrence wins Best of Breast Cancer Award Leading US Breast Surgeon, Dr. Richard Fine, presented data from IceCure's ICE3 study & discussed other recent publications on breast cancer cryoablation CAESAREA, Israel, July 25, 2025 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ:ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoabla

      7/25/25 9:00:00 AM ET
      $ICCM
      Medical/Dental Instruments
      Health Care
    • IceCure Reminds Shareholders of Upcoming Expiration of Rights Offering Subscription Period

      CAESAREA, Israel, July 24, 2025 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ:ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, reminds rights holders that the subscription period for its previously announced rights offering (the "Rights Offering") expires at 5:00 PM Eastern Time on Monday, July 28, 2025.   Pursuant to the Rights Offering, the Company distributed to all holders of record of the Company's ordinary shares, no par value per share ("Ordinary Shares") as of 5:00 p.m., Eastern Time, on July 9, 2025 (the "Record Date"), at no charge, non-transfe

      7/24/25 9:00:00 AM ET
      $ICCM
      Medical/Dental Instruments
      Health Care

    $ICCM
    Leadership Updates

    Live Leadership Updates

    See more
    • IceCure Medical Takes Next Major Initiative as it Prepares to Accelerate the Commercialization of ProSense in U.S. and Canada: Appoints VP of Sales, North America

      Mr. Shad Good brings nearly 20 years of medical device sales and leadership experience, including as U.S. Senior Director of Sales at a global leader in minimally invasive breast diagnostic and therapeutic systemsImmediate responsibility is to build out the sales infrastructure as the Company awaits the FDA response to its regulatory filing for early-stage low risk breast cancer in patients who are at high risk for surgery as well as the FDA's response to the final ICE3 results which are due in 2024 CAESAREA, Israel, Aug. 28, 2023 /PRNewswire/ -- IceCure Medical Ltd. ("IceCure" or the "Company") (NASDAQ:ICCM) developer of the ProSense® System, a minimally-invasive cryoablation technology tha

      8/28/23 8:00:00 AM ET
      $ICCM
      Medical/Dental Instruments
      Health Care
    • IceCure Appoints Vincent Chun Hung Chan to Serve as an Independent Director on its Board of Directors

      Galit Bar Malik promoted to VP of Operations and Service CAESAREA, Israel, Dec. 6, 2022 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ:ICCM) (TASE: ICCM) ("IceCure" or the "Company"), developer of minimally-invasive cryoablation technology, the ProSense® System that destroys tumors by freezing, today announced the appointment of Vincent Chun Hung Chan to serve as an independent director on the Company's board of directors. Mr. Chan has been a private equity executive for the past three decades, managing and leading more than 80 investment projects supporting company growth via funding and synergistic mergers and acquisitions. Since March 2021, he has been the Director of Samena Capital, a prin

      12/6/22 8:00:00 AM ET
      $ICCM
      Medical/Dental Instruments
      Health Care
    • IceCure Medical Announces Appointment of Merav Nir Dotan to Vice President Human Resources

      CAESAREA, Israel, Nov. 29, 2021 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ:ICCM) (TASE: ICCM) ("IceCure" or the "Company"), developer of minimally-invasive cryoablation technology, the ProSense® System, that destroys tumors by freezing as an alternative to surgical tumor removal, today announced the appointment of Mrs. Merav Nir Dotan to the new position of Vice President, Human Resources. Mrs. Nir Dotan has over two decades of experience in human resources and organizational management. "As the company continues to evolve, we believe investing in our Human Resources function commensurate with an investment in human capital so Mrs. Nir Dotan's appointment is key," stated Eyal Shamir, Chie

      11/29/21 1:07:00 PM ET
      $ICCM
      Medical/Dental Instruments
      Health Care

    $ICCM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by IceCure Medical Ltd.

      SC 13G/A - IceCure Medical Ltd. (0001584371) (Subject)

      11/14/24 9:38:43 PM ET
      $ICCM
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by IceCure Medical Ltd. (Amendment)

      SC 13G/A - IceCure Medical Ltd. (0001584371) (Subject)

      2/14/23 8:46:31 AM ET
      $ICCM
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by IceCure Medical Ltd. (Amendment)

      SC 13G/A - IceCure Medical Ltd. (0001584371) (Subject)

      1/24/23 5:04:22 PM ET
      $ICCM
      Medical/Dental Instruments
      Health Care

    $ICCM
    Financials

    Live finance-specific insights

    See more
    • IceCure Medical Reports First Quarter 2025 Financial Results

      Recently finalized and delivered proposed post market study plan to the FDA; Awaiting marketing authorization decision for ProSense® in women aged 70+ with early-stage low risk breast cancer Continues to see rising interest in North America for ProSense® Conference call to be held today at 10:00 am Eastern Time CAESAREA, Israel, May 28, 2025 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ:ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today reported financial results as of and for the three months ended March 31, 2025. IceCure delivered its proposed post

      5/28/25 8:30:00 AM ET
      $ICCM
      Medical/Dental Instruments
      Health Care
    • IceCure to Report First Quarter 2025 Financial & Operational Results on May 28, 2025

      CAESAREA, Israel, May 21, 2025 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ:ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today announced that it will issue a press release with its financial and operational results as of and for the three months ended March 31, 2025 before the Nasdaq Stock Market opens on Wednesday, May 28, 2025. The Company will also discuss such results and other corporate developments on a conference call at 10:00 a.m. EDT on the same day. Conference call & webcast info:Wednesday, May 28, 2025, at 10:00 am EDTUS: 1-888-407-2553Is

      5/21/25 8:30:00 AM ET
      $ICCM
      Medical/Dental Instruments
      Health Care
    • IceCure Medical Reports 2024 Financial Results: 42% Growth in ProSense® Cryoablation Sales in North America

      Expecting FDA decision on marketing authorization for early-stage low risk breast cancer with endocrine therapy Positive ProSense® results were reported through 33 peer-reviewed journals and medical conferences during 2024 Conference call to be held today at 10:00 am Eastern Time CAESAREA, Israel, March 27, 2025 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ:ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today reported financial results as of and for the twelve months ended December 31, 2024. IceCure continues to engage with the U.S. Food and Drug Admin

      3/27/25 8:30:00 AM ET
      $ICCM
      Medical/Dental Instruments
      Health Care